China Biotech Weekly #6: The NewCo Model — Why Chinese Biotechs Are Creating New Companies Instead of Licensing

This Week's Top Takeaway

The "NewCo" licensing model is the most significant structural innovation in China-to-West deal-making since the multi-asset framework. Instead of licensing assets to an existing Big Pharma, Chinese biotechs are creating new companies — capitalized by Western VCs and institutional investors — to develop their assets ex-China. The Chinese licensor retains more economic upside (equity + royalties vs. milestones only), and Western investors get direct equity exposure to Chinese innovation without the governance complexity of investing in China-listed entities.

BIOSECURE Watch

Status: 🟡 Monitoring

SEC BIOSECURE disclosures: approximately 8 companies have filed. Convergence on standard risk factor language continues.
OMB: no public activity on BCC list process
Congressional: no new developments on WuXi 1260H recommendation
WuXi AppTec (药明康德): Q4 2025 earnings call expected next week — analysts will probe BIOSECURE contingency planning and client retention

One development worth tracking: The NewCo model (described above) may have BIOSECURE implications. If a Chinese company creates a US-incorporated NewCo that contracts with WuXi for manufacturing, the BIOSECURE restriction applies to the NewCo's federal contracting — not the Chinese parent's. This adds a layer of structural complexity to compliance analysis.

CDE Filing Watch

Hengrui (恒瑞医药) filed a Phase II protocol amendment for HRS-9821 (PDE3/4 inhibitor, the lead asset in the GSK deal). The amendment expands the patient population — consistent with GSK's strategy to position this asset across the widest spectrum of COPD patients.

BeiGene (百济神州) received CDE approval for a new zanubrutinib combination regimen in mantle cell lymphoma. BeiGene continues to expand the zanubrutinib label through CDE before pursuing parallel FDA approvals — a strategy that generates Chinese clinical data faster and cheaper than US-first development.

Takeaways for BD Teams

If you're only offering traditional licenses, you're competing against NewCos offering equity. Chinese biotechs with high-value assets increasingly prefer the NewCo economics. Adjust your deal structures or lose to the VC-backed alternative.

The NewCo model creates new competitors. A Western-capitalized NewCo with a licensed Chinese asset is a new entrant in your therapeutic area — and it has VC backing, focused management, and a motivated Chinese partner. Track these entities as competitive threats, not just deal structures.

BIOSECURE applies to NewCos too. A US-incorporated entity that contracts with designated BCCs faces the same restrictions as any other federal contractor. The NewCo structure doesn't create a BIOSECURE safe harbor.

Watch BeiGene's CDE-first, FDA-second strategy. Generating Chinese clinical data before pursuing US registration is becoming the standard playbook. BD teams should be monitoring CDE trial registrations 12-18 months before US IND filings — that's your scouting window.

China Biotech Weekly is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan